SANTA CLARA, Calif.--(BUSINESS WIRE)--XenoPort, Inc. (Nasdaq:XNPT) announced today that it will present data on a new preclinical product candidate, XP23829, at the upcoming 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) meeting in Gothenburg, Sweden, October 13 - 16, 2010. Data from the poster presentation show that compared to dimethylfumarate (DMF), molar equivalent doses of XP23829, a novel prodrug of methylhydrogenfumarate (MHF), provided:
